1. Home
  2. RCKT vs NHIC Comparison

RCKT vs NHIC Comparison

Compare RCKT & NHIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCKT
  • NHIC
  • Stock Information
  • Founded
  • RCKT 1999
  • NHIC 2024
  • Country
  • RCKT United States
  • NHIC United States
  • Employees
  • RCKT N/A
  • NHIC N/A
  • Industry
  • RCKT Biotechnology: Pharmaceutical Preparations
  • NHIC
  • Sector
  • RCKT Health Care
  • NHIC
  • Exchange
  • RCKT Nasdaq
  • NHIC NYSE
  • Market Cap
  • RCKT 328.6M
  • NHIC 276.7M
  • IPO Year
  • RCKT N/A
  • NHIC 2025
  • Fundamental
  • Price
  • RCKT $3.14
  • NHIC $10.19
  • Analyst Decision
  • RCKT Buy
  • NHIC
  • Analyst Count
  • RCKT 13
  • NHIC 0
  • Target Price
  • RCKT $14.79
  • NHIC N/A
  • AVG Volume (30 Days)
  • RCKT 3.6M
  • NHIC 120.0
  • Earning Date
  • RCKT 08-08-2025
  • NHIC 01-01-0001
  • Dividend Yield
  • RCKT N/A
  • NHIC N/A
  • EPS Growth
  • RCKT N/A
  • NHIC N/A
  • EPS
  • RCKT N/A
  • NHIC N/A
  • Revenue
  • RCKT N/A
  • NHIC N/A
  • Revenue This Year
  • RCKT N/A
  • NHIC N/A
  • Revenue Next Year
  • RCKT $608.87
  • NHIC N/A
  • P/E Ratio
  • RCKT N/A
  • NHIC N/A
  • Revenue Growth
  • RCKT N/A
  • NHIC N/A
  • 52 Week Low
  • RCKT $2.19
  • NHIC $10.02
  • 52 Week High
  • RCKT $26.98
  • NHIC $10.55
  • Technical
  • Relative Strength Index (RSI)
  • RCKT 49.02
  • NHIC N/A
  • Support Level
  • RCKT $3.03
  • NHIC N/A
  • Resistance Level
  • RCKT $3.54
  • NHIC N/A
  • Average True Range (ATR)
  • RCKT 0.21
  • NHIC 0.00
  • MACD
  • RCKT 0.09
  • NHIC 0.00
  • Stochastic Oscillator
  • RCKT 49.37
  • NHIC 0.00

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

About NHIC NEWHOLD INVESTMENT CORP III

NewHold Investment Corp III is a blank check company.

Share on Social Networks: